Table 1.

P2Y₁₂ receptor inhibitors

Drug	Route	Action	Dosing (bolus/maintenance)	Peak effect	Main studies
Clopidogrel	Oral	Irreversible Hepatic metabolization	600 mg 75 mg/d	3 h	CURE-PCI CLARITY-PCI
Prasugrel	Oral	Irreversible Hepatic metabolization	60 mg 10 mg/d	30 min	TRITON-TIMI 18
Cangrelor	IV	Reversible Direct inhibition	30μ/Kg/min 4 μ/Kg/min	1 min	CHAMPION - PLATFORM
Ticagrelor	Oral	Reversible Direct inhibition	180 mg 90 mg 12/12 h	30 min	PLATO

CURE-PCI (Effects of pretreatment with Clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention)¹⁰; CLARITY-PCI (Effect of Clopidogrel pretreatment before percutaneous coronary intervention in patients with ST elevation myocardial infarction treated with fibrinolytics)¹¹; TRITON-TIMI 18 (Prasugrel versus Clopidogrel in patients with acute coronary syndromes)¹²; PLATO(Ticagrelor versus Clopidogrel in patients with acute coronary syndromes)¹³; CHAMPION-PLATFORM (Intravenous platelet blockade with cangrelor during PCI)¹⁴.